JP2015523072A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523072A5
JP2015523072A5 JP2015520567A JP2015520567A JP2015523072A5 JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5 JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015520567 A JP2015520567 A JP 2015520567A JP 2015523072 A5 JP2015523072 A5 JP 2015523072A5
Authority
JP
Japan
Prior art keywords
composition
purified recombinant
seq
conversion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523072A (ja
JP6171007B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/048561 external-priority patent/WO2014005014A2/en
Publication of JP2015523072A publication Critical patent/JP2015523072A/ja
Publication of JP2015523072A5 publication Critical patent/JP2015523072A5/ja
Application granted granted Critical
Publication of JP6171007B2 publication Critical patent/JP6171007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520567A 2012-06-29 2013-06-28 組換えイズロン酸2スルファターゼの精製 Active JP6171007B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
US61/666,733 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060910A Division JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸2スルファターゼの精製

Publications (3)

Publication Number Publication Date
JP2015523072A JP2015523072A (ja) 2015-08-13
JP2015523072A5 true JP2015523072A5 (enExample) 2016-01-07
JP6171007B2 JP6171007B2 (ja) 2017-07-26

Family

ID=49778401

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015520567A Active JP6171007B2 (ja) 2012-06-29 2013-06-28 組換えイズロン酸2スルファターゼの精製
JP2016060910A Active JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸2スルファターゼの精製
JP2018067404A Withdrawn JP2018121645A (ja) 2012-06-29 2018-03-30 組換えイズロン酸2スルファターゼの精製
JP2020037811A Active JP7594365B2 (ja) 2012-06-29 2020-03-05 組換えイズロン酸2スルファターゼの精製

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016060910A Active JP6505629B2 (ja) 2012-06-29 2016-03-24 組換えイズロン酸2スルファターゼの精製
JP2018067404A Withdrawn JP2018121645A (ja) 2012-06-29 2018-03-30 組換えイズロン酸2スルファターゼの精製
JP2020037811A Active JP7594365B2 (ja) 2012-06-29 2020-03-05 組換えイズロン酸2スルファターゼの精製

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP2867245B1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN104583225A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA2877517C (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA034549B1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY192068A (enExample)
NZ (3) NZ743910A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871B1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI553120B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
BR112019003622A2 (pt) 2016-08-25 2019-05-21 Jcr Pharmaceuticals Co., Ltd. método para produção de uma proteína de fusão.
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
EP3833377B1 (en) 2018-08-10 2023-11-22 Alexion Pharmaceuticals, Inc. Bone healing at implants using alkaline phosphatase
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸-2-スルファターゼ免疫グロブリン融合タンパク質の精製
US20220098279A1 (en) * 2019-01-30 2022-03-31 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
US12433938B2 (en) 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
KR20230088811A (ko) * 2020-10-23 2023-06-20 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제의 제조 동안 총 시알산 함량(tsac)을 제어하는 방법
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
US7541164B2 (en) 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2−oスルファターゼ組成物および関連の方法
EP2325302B1 (en) 2003-02-11 2016-01-06 Shire Human Genetic Therapies, Inc. Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
KR20080111487A (ko) 2006-03-20 2008-12-23 메다렉스, 인코포레이티드 단백질 정제 방법
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
AR070198A1 (es) * 2008-01-18 2010-03-17 Biomarin Pharm Inc Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
ES2643015T3 (es) * 2010-06-25 2017-11-21 Shire Human Genetic Therapies, Inc. Tratamiento del Síndrome de Sanfilippo Tipo B
HRP20191924T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Similar Documents

Publication Publication Date Title
JP2015523072A5 (enExample)
AR091647A1 (es) Purificacion de iduronato-2-sulfatasa
PH12013501213A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
HRP20160490T4 (hr) Pripravak i oblik koji sadrže rekombinantnu humanu iduronat-2-sulfatazu te postupci njihove pripreme
JP2007175057A5 (enExample)
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
WO2010057203A3 (en) Hdl particles for delivery of nucleic acids
DK2343320T3 (da) Anti-gitr-antistoffer og anvendelser deraf
HK1206764A1 (en) Nutritive proteins and methods
HK1206762A1 (en) Nutritive fragments and proteins with low or no phenylalanine and methods
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
BR112015009201A2 (pt) composição compreendeendo um polipeptídeo recombinante, ácido nucleico codificando o mesmo, célula hospedeira, bem como métodos para produzir uma beta-glucosidase e para hidrolisar um substrato de biomassa lignocelulósica
RU2015112625A (ru) Пептид, применение пептида для лечения сердечно-сосудистых заболеваний, нуклеотидная последовательность, вектор экспрессии, хозяйская клетка, фармацевтическая композиция
JP2015533791A5 (enExample)
HK1206763A1 (en) Charged nutritive fragments, proteins and methods
WO2013016724A3 (en) Decarboxylase proteins with high keto-isovalerate decarboxylase activity
BR112014003841A2 (pt) estratégia de múltiplas cópias para produção em alto título e alta pureza de proteínas de múltiplas subunidades tal como anticorpos em micróbios transformados tal como pichia pastoris
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
HRP20161009T1 (hr) Modificirani omci kao inhibitor komplementa
EP3263123A3 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
BR112012008655A2 (pt) formulação detergente em dose distinta ou única.
BR112014011664A2 (pt) mutantes de hidantoínase
JP2013542954A5 (enExample)
WO2011156252A3 (en) Sulfation of wnt pathway proteins
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides